Efficacy and safety of insulin glargine in type 2 diabetic patients with renal failure

Niafar, M. and Nakhjavani, M. and Esteghamati, A. and Ziaie, A. and Jahed, S. A. and Azmandian, J. and Khamseh, M. E. and Yousefzadeh, G. and Gozashti, M. H. and Malek, M. (2012) Efficacy and safety of insulin glargine in type 2 diabetic patients with renal failure. International Journal of Diabetes and Metabolism, 3 (4).

[img] Text
EfficacyandSafetyofInsulinGlargine.pdf

Download (2MB)

Abstract

Aim and Background: In patients with type 2 diabetes mellitus complicated with renal failure achieving good glucose control and reduction of risk of hypoglycemia should be balanced. The aim of this study was to determine the safety and efficacy of insulin glargine in type 2 diabetic patients with diabetic nephropathy. Methods: A total of 89 subjects with type 2 diabetes (mean age 62.9 ± 10.7 and diabetes duration 13.9 ± 7.6 years) who had diabetic nephropathy (mean Glomerular FiltrationR GFR 34.1 ± 11.5 ml/min) were included in the study. Patients who were not optimally controlled or experienced frequent hypoglycemia on Oral Antidiabetic Drugs (OAD) or NPH insulin received insulin glargine at bedtime. The starting dose was 0.1 unit/Kg and adjusted to obtain target fasting blood glucose (5-7.2 mmol/l). The medical records were obtained before and 2 and 4 months after beginning insulin glargine. Results: At the end of four month treatment period, significant reduction in glycated hemoglobin (HbA1c) was observed (from 8.4% ± 1.6 to 7.7% ± 1.2) (p<0.001). The treatments were associated with significant reduction in fasting glucose levels (from 159.7 ± 67 to 119.4 ± 28.4mg/dl) (p<0.001).Patients’ Body Mass Index (BMI) did not increase at the end of study (26.2 ± 3.9 and 26.2 ± 3.8 kg/m2) (p=0.96). Mild symptomatic hypoglycemia was seen in 12.5% of subjects. No other side effects were noted throughout the study. Conclusion: Insulin glargine improved HbA1c at short-term and proved to be safe and well tolerated in type 2 diabetic patients with diabetic nephropathy. © 2012 Niafar M, et al.

Item Type: Article
Additional Information: Cited By :6 Export Date: 16 February 2020 CODEN: IJDMB Correspondence Address: Niafar, M.; Endocrinology and Metabolism Section, Department of Medicine, Imam Reza Hospital, Tabriz University of Medical SciencesIran; email: drniafar@yahoo.com
Uncontrolled Keywords: Diabetic nephropathy Hypoglycemia Insulin glargine
Subjects: WD Nutrition Disease and metabolic diseases
WJ Urogenital System
QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib5 lib5
Date Deposited: 05 May 2020 06:25
Last Modified: 05 May 2020 06:25
URI: http://eprints.mums.ac.ir/id/eprint/19015

Actions (login required)

View Item View Item